Urgent need for enhanced thrombosis products in Europe, says F&S

The increasing incidence of thrombosis, paralleled by the maturing life cycles of existing products, are motivating the need for novel alternatives. Establishing end-user confidence and ensuring cost-effectiveness pose significant challenges to market advancement, notes market research firm Frost & Sullivan.

However, the launch of three blockbuster oral anticoagulants is projected to help the thrombosis therapeutics market address these challenges. It is also anticipated to help companies tackle competition from low cost generics.

"The rising number of people suffering from thrombosis is resulting in higher demand for related therapeutics," notes Frost & Sullivan research analyst Deepika Pramod Chopda, adding: "This, coupled with strong pipeline development, is pushing robust growth in the overall market."